<abstract xmlns="http://www.w3.org/1999/xhtml">
				
				Background. The attempt to act on several signalling pathways involved in tumour development simultaneously appears to be more attractive than attacking a single target structure alone. Vascular endothelial growth factor (VEGF) over-expression is frequently observed in human epidermal growth factor receptor 2 (Her2/neu) positive patients with breast cancer and over-expression of the proto-oncogene Her2/neu is associated with an up-regulation of VEGF. 
				Case report. The case of a Her2/neu positive patient with breast cancer who refused cytotoxic chemotherapy with its potential side effects as well as mastectomy is presented. Our patient has been receiving the combined double administration of bevacizumab and trastuzumab for more than 4 years. 
				Conclusions. This case report shows that (a) the combined double administration of bevacizumab and trastuzumab was be clinically effective. (b) The combination of bevacizumab and trastuzumab is safe and non-toxic. (c) Bevacizumab and trastuzumab can be used as a long-term application
			</abstract>

Background. The attempt to act on several signalling pathways involved in tumour development simultaneously appears to be more attractive than attacking a single target structure alone. Vascular endothelial growth factor (VEGF) over-expression is frequently observed in human epidermal growth factor receptor 2 (Her2/neu) positive patients with breast cancer and over-expression of the proto-oncogene Her2/neu is associated with an up-regulation of VEGF. 
				Case report. The case of a Her2/neu positive patient with breast cancer who refused cytotoxic chemotherapy with its potential side effects as well as mastectomy is presented. Our patient has been receiving the combined double administration of bevacizumab and trastuzumab for more than 4 years. 
				Conclusions. This case report shows that (a) the combined double administration of bevacizumab and trastuzumab was be clinically effective. (b) The combination of bevacizumab and trastuzumab is safe and non-toxic. (c) Bevacizumab and trastuzumab can be used as a long-term application

Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab

Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) – LB Cluster Translational Oncology, 3rd Medical Department – Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria / Applied Cancer Research – Institution for Translational Research Vienna (ACR –ITR VIEnna), Vienna, Austria

Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3rd Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria

Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3rd Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria/ Applied Cancer Research – Institution for Translational Research Vienna (ACR –ITR VIEnna), Vienna, Austria

Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3rd Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria / Institute for Radiodiagnostics, Kaiser Franz Josef-Spital, Vienna, Austria

Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3rd Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria / Applied Cancer Research – Institution for Translational Research Vienna (ACR –ITR VIEnna), Vienna, Austria

Radiology and Oncology

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The attempt to act on several signalling pathways involved in tumour development simultaneously appears to be more attractive than attacking a...

Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab

Publicado en línea: 25 abr 2014

Páginas: 184 - 188

Recibido: 27 ago 2013

Aceptado: 18 nov 2013

DOI: https://doi.org/10.2478/raon-2013-0083

Palabras clave
breast cancer, Her2/neu, trastuzumab, bevacizumab, VEGF

© by Robert Königsberg

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab

Publicado en línea: 25 abr 2014

Páginas: 184 - 188

Recibido: 27 ago 2013

Aceptado: 18 nov 2013

DOI: https://doi.org/10.2478/raon-2013-0083

Palabras clavebreast cancer, Her2/neu, trastuzumab, bevacizumab, VEGF

© by Robert Königsberg

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Palabras clave
breast cancer, Her2/neu, trastuzumab, bevacizumab, VEGF